Alnylam Pharmaceuticals, Inc. (LON: 0HD2)
London
· Delayed Price · Currency is GBP · Price in USD238.00
-6.60 (-2.70%)
Dec 23, 2024, 5:21 PM BST
Alnylam Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 29, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 30, 2022 | Dec '21 Dec 30, 2021 | Dec '20 Dec 30, 2020 | Dec '19 Dec 30, 2019 | 2018 - 2014 |
| Revenue | 2,095 | 1,828 | 1,037 | 844.29 | 492.85 | 219.75 | Upgrade
|
| Revenue Growth (YoY) | 21.54% | 76.23% | 22.88% | 71.31% | 124.28% | 193.36% | Upgrade
|
| Cost of Revenue | 306.41 | 310.41 | 168.82 | 140.14 | 78.05 | 25.06 | Upgrade
|
| Gross Profit | 1,788 | 1,518 | 868.6 | 704.14 | 414.8 | 194.69 | Upgrade
|
| Selling, General & Admin | 878.31 | 795.65 | 770.66 | 620.64 | 588.42 | 533.66 | Upgrade
|
| Research & Development | 1,098 | 1,004 | 883.02 | 792.16 | 654.82 | 600.46 | Upgrade
|
| Operating Expenses | 1,977 | 1,800 | 1,654 | 1,413 | 1,243 | 1,134 | Upgrade
|
| Operating Income | -188.13 | -282.18 | -785.07 | -708.65 | -828.44 | -939.43 | Upgrade
|
| Interest Expense | -134.23 | -121.22 | -155.97 | -143.02 | -84.5 | - | Upgrade
|
| Interest & Investment Income | 121.38 | 95.56 | 24.81 | 1.58 | 11.81 | 33.45 | Upgrade
|
| Other Non Operating Income (Expenses) | -118.04 | -108.74 | -100.86 | -57.75 | -8.52 | 9.44 | Upgrade
|
| EBT Excluding Unusual Items | -319.02 | -416.57 | -1,017 | -907.84 | -909.64 | -896.54 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2.09 | -16.94 | -33.31 | 55.7 | 54.04 | 11.29 | Upgrade
|
| Other Unusual Items | - | - | -76.59 | - | - | - | Upgrade
|
| Pretax Income | -321.1 | -433.52 | -1,127 | -852.14 | -855.6 | -885.25 | Upgrade
|
| Income Tax Expense | 11.16 | 6.73 | 4.16 | 0.68 | 2.68 | 0.86 | Upgrade
|
| Net Income | -332.26 | -440.24 | -1,131 | -852.82 | -858.28 | -886.12 | Upgrade
|
| Net Income to Common | -332.26 | -440.24 | -1,131 | -852.82 | -858.28 | -886.12 | Upgrade
|
| Shares Outstanding (Basic) | 127 | 125 | 122 | 118 | 115 | 109 | Upgrade
|
| Shares Outstanding (Diluted) | 127 | 125 | 122 | 118 | 115 | 109 | Upgrade
|
| Shares Change (YoY) | 1.97% | 2.64% | 2.73% | 3.01% | 5.24% | 8.62% | Upgrade
|
| EPS (Basic) | -2.62 | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | Upgrade
|
| EPS (Diluted) | -2.62 | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | Upgrade
|
| Free Cash Flow | 16.06 | 41.95 | -613.33 | -718.07 | -685.32 | -418.58 | Upgrade
|
| Free Cash Flow Per Share | 0.13 | 0.34 | -5.04 | -6.06 | -5.96 | -3.83 | Upgrade
|
| Gross Margin | 85.37% | 83.02% | 83.73% | 83.40% | 84.16% | 88.60% | Upgrade
|
| Operating Margin | -8.98% | -15.43% | -75.68% | -83.93% | -168.09% | -427.50% | Upgrade
|
| Profit Margin | -15.86% | -24.08% | -109.04% | -101.01% | -174.15% | -403.24% | Upgrade
|
| Free Cash Flow Margin | 0.77% | 2.29% | -59.12% | -85.05% | -139.05% | -190.48% | Upgrade
|
| EBITDA | -132.15 | -228.12 | -740.6 | -661.09 | -793.67 | -922.26 | Upgrade
|
| EBITDA Margin | -6.31% | -12.48% | -71.39% | -78.30% | -161.03% | - | Upgrade
|
| D&A For EBITDA | 55.98 | 54.05 | 44.47 | 47.57 | 34.77 | 17.18 | Upgrade
|
| EBIT | -188.13 | -282.18 | -785.07 | -708.65 | -828.44 | -939.43 | Upgrade
|
| EBIT Margin | -8.98% | -15.43% | -75.68% | -83.93% | -168.09% | - | Upgrade
|
| Revenue as Reported | 2,095 | 1,828 | 1,037 | 844.29 | 492.85 | 219.75 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.